Tracer-based assessments of hepatic anaplerotic and TCA cycle flux: practicality, stoichiometry, and hidden assumptions.
Two groups recently used different tracer methods to quantify liver-specific flux rates. The studies had a similar goal, i.e., to characterize mitochondrial oxidative function. These efforts could have a direct impact on our ability to understand metabolic abnormalities that affect the pathophysiology of fatty liver and allow us to examine mechanisms surrounding potential therapeutic interventions. Briefly, one method couples the continuous infusion of [(13)C]acetate with direct real-time measurements of [(13)C]glutamate labeling in liver; the other method administers [(13)C]propionate, in combination with other tracers, and subsequently measures the (13)C labeling of plasma glucose and/or acetaminophen-glucuronide. It appears that a controversy has arisen, since the respective methods yielded different estimates of the anaplerotic/TCA flux ratio (VANA:VTCA) in "control" subjects, i.e., the [(13)C]acetate- and [(13)C]propionate-derived VANA:VTCA flux ratios appear to be ∼1.4 and ∼5, respectively. While the deep expertise in the respective groups makes it somewhat trivial for each to perform the tracer studies, the data interpretation is inherently difficult. The current perspective was undertaken to examine potential factors that could account for or contribute to the apparent differences. Attention was directed toward 1) matters of practicality, 2) issues surrounding stoichiometry, and 3) hidden assumptions. We believe that the [(13)C]acetate method has certain weaknesses that limit its utility; in contrast, the [(13)C]propionate method likely yields a more correct answer. We hope our discussion will help clarify the differences in the recent reports. Presumably this will be of interest to investigators who are considering tracer-based studies of liver metabolism.
Merck Research Laboratories, Kenilworth, New Jersey stephen_previs@merck.com.
Stephen F
SF
Previs
Merck Research Laboratories, Kenilworth, New Jersey.
David E
DE
Kelley
D000082:Acetaminophen / Q000031:analogs & derivatives / Q000378:metabolism; D000085:Acetates; D001786:Blood Glucose / Q000378:metabolism; D002247:Carbon Isotopes; D002952:Citric Acid Cycle; D005234:Fatty Liver / Q000378:metabolism*; D018698:Glutamic Acid / Q000378:metabolism; D006801:Humans; D008099:Liver / Q000378:metabolism*; D064688:Metabolic Flux Analysis / Q000379:methods* / Q000592:standards; D008928:Mitochondria / Q000378:metabolism; D008930:Mitochondria, Liver / Q000378:metabolism*; D010084:Oxidation-Reduction; D011422:Propionates; D011849:Radioactive Tracers
D000085:Acetates; D001786:Blood Glucose; D002247:Carbon Isotopes; D011422:Propionates; D011849:Radioactive Tracers; D000082:Acetaminophen; D018698:Glutamic Acid; C037386:acetaminophen glucuronide
NASH; diabetes; fatty liver; insulin resistance; metabolic disease; stable isotopes